ALLARITY THERAPEUTICS INC (ALLR) Stock Fundamental Analysis
NASDAQ:ALLR - Nasdaq - US0167445008 - Common Stock - Currency: USD
Taking everything into account, ALLR scores 2 out of 10 in our fundamental rating. ALLR was compared to 572 industry peers in the Biotechnology industry. ALLR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALLR does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
ALLR had negative earnings in the past year.
ALLR had a negative operating cash flow in the past year.
In the past 5 years ALLR always reported negative net income.
In the past 5 years ALLR always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of ALLR (-95.31%) is worse than 74.16% of its industry peers.
ALLR's Return On Equity of -149.82% is on the low side compared to the rest of the industry. ALLR is outperformed by 63.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -95.31% | ||
| ROE | -149.82% | ||
| ROIC | N/A |
ROA(3y)-123.51%
ROA(5y)-87.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ALLR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for ALLR has been increased compared to 1 year ago.
ALLR has a better debt/assets ratio than last year.
2.2 Solvency
ALLR has an Altman-Z score of -8.87. This is a bad value and indicates that ALLR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.87, ALLR is doing worse than 72.04% of the companies in the same industry.
There is no outstanding debt for ALLR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.87 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 2.75 indicates that ALLR has no problem at all paying its short term obligations.
ALLR has a Current ratio of 2.75. This is in the lower half of the industry: ALLR underperforms 68.67% of its industry peers.
ALLR has a Quick Ratio of 2.75. This indicates that ALLR is financially healthy and has no problem in meeting its short term obligations.
ALLR has a Quick ratio of 2.75. This is in the lower half of the industry: ALLR underperforms 66.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.75 | ||
| Quick Ratio | 2.75 |
3. Growth
3.1 Past
ALLR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.71%, which is quite impressive.
EPS 1Y (TTM)99.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
ALLR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.92% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.94%
EPS Next 2Y41.41%
EPS Next 3Y25.98%
EPS Next 5Y18.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ALLR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALLR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ALLR's earnings are expected to grow with 25.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.41%
EPS Next 3Y25.98%
5. Dividend
5.1 Amount
No dividends for ALLR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ALLARITY THERAPEUTICS INC
NASDAQ:ALLR (1/23/2025, 8:42:41 PM)
Premarket: 1.18 -0.14 (-10.61%)1.32
+0.31 (+30.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1.2%
Inst Owner Change0%
Ins Owners12.32%
Ins Owner Change48.48%
Market Cap5.85M
Analysts43.33
Price TargetN/A
Short Float %6.33%
Short Ratio0.24
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.85%
Min EPS beat(2)11.28%
Max EPS beat(2)62.42%
EPS beat(4)2
Avg EPS beat(4)-282.05%
Min EPS beat(4)-1133.29%
Max EPS beat(4)62.42%
EPS beat(8)5
Avg EPS beat(8)-136.82%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2900%
EPS NY rev (1m)0%
EPS NY rev (3m)-2900%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.45 | ||
| P/tB | 0.45 | ||
| EV/EBITDA | N/A |
EPS(TTM)-933.21
EYN/A
EPS(NY)-47.86
Fwd EYN/A
FCF(TTM)-3.57
FCFYN/A
OCF(TTM)-3.57
OCFYN/A
SpS0
BVpS2.93
TBVpS2.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -95.31% | ||
| ROE | -149.82% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-123.51%
ROA(5y)-87.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.75 | ||
| Quick Ratio | 2.75 | ||
| Altman-Z | -8.87 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.43%
EPS Next Y99.94%
EPS Next 2Y41.41%
EPS Next 3Y25.98%
EPS Next 5Y18.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.37%
OCF growth 3YN/A
OCF growth 5YN/A